M. Zacharin and G. Warne


Department of Endocrinology and Diabetes, Royal Children's Hospital, Parkville, Victoria, Australia.


Abstract

AIMS — Long acting subcutaneous testosterone pellets are of proved efficacy for the treatment of hypogonadal men, but have not been reported as a treatment modality in adolescent boys. Pharmacodynamic studies of subcutaneous testosterone release have shown prolonged normalisation of testosterone levels for at least four months. Administration of a long acting, safe, effective, and convenient form of treatment is desirable when life- long treatment is indicated.


PATIENTS AND METHODS—Eighteen boys (aged 13.9-17.5 years at the start of treatment)—seven with primary hypogonadism, nine with secondary hypogonadism, and two boys being treated with testosterone for tall stature — were given testosterone pellets (8-10 mg/kg) every six months for 18months. Height, weight, pubertal status, and psychosocial parameters were assessed and follicle stimulating hormone, luteinising hormone, testosterone, prolactin, and lipids were measured at 0, 1, 3,6, 12, and 18 months. Bone age was measured at 0 and 12months.


RESULTS — In all boys growth velocity continued appropriately for bone age. Puberty continued to progress in all boys and in two boys the amount of virilisation exceeded that seen with previous treatment with intramuscular testosterone. After testosterone administration, follicle stimulating hormone and luteinising hormone suppressed incompletely in the boys with primary hypogonadism. Serum testosterone ranged from 4.3 to 26.7 nmol/l at three months to less than 10nmol/l at six months after implantation. Prolactin and lipid levels were normal throughout the study. By report, there was an improvement in mood and emotional wellbeing. No pellet extrusions occurred in a total of 156 pellet insertions.


CONCLUSIONS — All boys preferred this mode of testosterone administration to intramuscular injections. Long acting subcutaneous testosterone pellets are safe, efficacious, well tolerated, and convenient, and result in normal physical growth and improved psychological outlook in adolescent hypogonadal boys.


  • Continued normal progress of growth and pubertal status occurs with subcutaneous testosterone
  • Prolonged stable physiological levels of testosterone are maintained for four to six months
  • Bone age advance is commensurate with change in chronological age
  • Psychological outlook and self image are reported to be improved
  • Subcutaneous testosterone is safe, well tolerated, efficacious, and convenient



Selected References


Conway AJ, Boylan LM, Howe C, Ross G, Handelsman DJ. Randomized clinical trial of testosterone replacement therapy in hypogonadal men. Int J Androl. 1988 Aug;11(4):247-264. [PubMed] 

Handelsman DJ, Conway AJ, Boylan LM. Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J Clin Endocrinol Metab. 1990 Jul;71 (1):216-222. [PubMed] 

Bagatell CJ, Bremner WJ. Androgens in men--uses and abuses. N Engl J Med. 1996 Mar 14;334(11):707-714. [PubMed] 

Albanese A, Kewley GD, Long A, Pearl KN, Robins DG, Stanhope R. Oral treatment for constitutional delay of growth and puberty in boys: a randomised trial of an anabolic steroid or testosterone undecanoate. Arch Dis Child. 1994 Oct;71(4):315-317. [PubMed] 

Plymate SR, Leonard JM, Paulsen CA, Fariss BL, Karpas AE. Sex hormone-binding globulin changes with androgen replacement. J Clin Endocrinol Metab. 1983 Sep;57(3):645-648. [PubMed] 

Richman RA, Kirsch LR. Testosterone treatment in adolescent boys with constitutional delay in growth and development. N Engl J Med. 1988 Dec 15;319(24):1563-1567. [PubMed] 

Rosenfeld RG, Northcraft GB, Hintz RL. A prospective, randomized study of testosterone treatment of constitutional delay of growth and development in male adolescents. Pediatrics. 1982 Jun;69(6):681-687. [PubMed] 

Decker MH, Loriaux DL, Cutler GB., Jr A seminiferous tubular factor is not obligatory for regulation of plasma follicle-stimulating hormone in the rat. Endocrinology. 1981 Mar;108 (3):1035-1039. [PubMed] 

Dunn JF, Nisula BC, Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab. 1981 Jul;53(1):58-68. [PubMed] 

Sokol RZ, Palacios A, Campfield LA, Saul C, Swerdloff RS. Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertil Steril. 1982 Mar;37(3):425- 430. [PubMed] 

Cantrill JA, Dewis P, Large DM, Newman M, Anderson DC. Which testosterone replacement therapy? Clin Endocrinol (Oxf). 1984 Aug;21 (2):97-107. [PubMed] 

O'Carroll R, Shapiro C, Bancroft J. Androgens, behaviour and nocturnal erection in hypogonadal men: the effects of varying the replacement dose. Clin Endocrinol (Oxf). 1985 Nov;23(5):527-538. [PubMed] 

Anderson RA, Bancroft J, Wu FC. The effects of exogenous testosterone on sexuality and mood of normal men. J Clin Endocrinol Metab. 1992 Dec;75(6):1503-1507. [PubMed] 

Bagatell CJ, Heiman JR, Rivier JE, Bremner WJ. Effects of endogenous testosterone and estradiol on sexual behavior in normal young men. J Clin Endocrinol Metab. 1994 Mar;78(3):711-716. [PubMed] 

Findlay J. The nature of inhibin and its use in the regulation of fertility and diagnosis of infertility. Fertil Steril. 1986 Nov;46(5):770-783. [PubMed]